Follow-up study for people treated for alcoholic liver scarring

This Phase 3 trial tests whether a cell medicine called Cellgram-LC, delivered through a catheter into the liver artery, is safer and works better for people with alcoholic cirrhosis. It may help improve outcomes in people with more advanced liver scarring.

This Phase 2 study tests whether SAMe can help people with alcoholic cirrhosis (scarred liver) who are in early to mid stages. It may also include healthy volunteers to compare safety and blood/body measurements.

This trial tests if an optimized treatment plan can improve remission in people with liver cirrhosis caused by alcohol. It aims to help patients achieve better health outcomes.

This trial tests a treatment made from stem cells to see if it is safe and can help reduce scarring and improve liver function in people with liver cirrhosis. It focuses on patients with moderate liver disease (Child-Pugh Class B).

This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.

This study compares patterns of liver inflammation and the liver’s healing ability in people with alcohol-related liver disease, using blood tests and (in most cases) a liver tissue sample. It may help doctors better understand what is happening in the liver and how it may recover.